Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
Previous Symbol
CUSIP64125C10
Phone858-617-7600
Debt
Debt-to-Equity RatioN/A
Current Ratio1.57
Quick Ratio1.55
Price-To-Earnings
Trailing P/E Ratio-56.79
Forward P/E Ratio535.29
P/E Growth27.29
Sales & Book Value
Annual Sales$161.63 million
Price / Sales51.05
Cash FlowN/A
Price / CashN/A
Book Value$4.93 per share
Price / Book18.46
Profitability
EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins2.40%
Return on Equity2.54%
Return on Assets1.17%
Miscellaneous
Employees400
Outstanding Shares90,680,000
Market Cap$9.02 billion
OptionableOptionable
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its earnings results on Monday, November, 5th. The company reported $0.52 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.48 by $0.04. The company earned $151.80 million during the quarter, compared to the consensus estimate of $151.51 million. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. Neurocrine Biosciences's revenue was up 149.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.13) earnings per share. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
What price target have analysts set for NBIX?
16 Wall Street analysts have issued 1-year target prices for Neurocrine Biosciences' shares. Their forecasts range from $99.00 to $162.00. On average, they expect Neurocrine Biosciences' share price to reach $125.75 in the next year. This suggests a possible upside of 36.7% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.
What is the consensus analysts' recommendation for Neurocrine Biosciences?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.
What are Wall Street analysts saying about Neurocrine Biosciences stock?
Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $150 on NBIX. On Tuesday, we hosted a call with a physician who has deep expertise in movement disorders and is familiar with, arguably pioneered, the use of VMAT2 inhibitors in various hyperkinetic disorders, having treated thousands of pediatric Tourette Syndrome (pTS) patients. Our discussion focused on the KOL’s views on the current TS treatment landscape, unmet needs, and efficacy of VMAT2i’s. Although some investors may be skeptical of valbenazine efficacy in pTS after 2 prior study failures (one in adult and another in pTS), we are optimistic about PoS of the ongoing pTS trial. Based, in part, on our recent KOL diligence including this call, we have increased conviction in not only the probability of T-Force GOLD success, but also in the market opportunity for valbe’ in TS." (9/14/2018)
- 2. Needham & Company LLC analysts commented, "Mesoblast announced good news that remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft- versus-host disease (GvHD)." (2/22/2018)
Has Neurocrine Biosciences been receiving favorable news coverage?
Media coverage about NBIX stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP).
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 60)
- Mr. Matthew C. Abernethy, Chief Financial Officer (Age 38)
- Dr. Haig P. Bozigian, Chief Devel. Officer (Age 60)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
Who are Neurocrine Biosciences' major shareholders?
Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (7.90%), Perceptive Advisors LLC (5.27%), BB Biotech AG (3.48%), Alliancebernstein L.P. (1.22%), First Trust Advisors LP (1.13%) and Pictet Asset Management Ltd. (0.97%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.
Which major investors are selling Neurocrine Biosciences stock?
NBIX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., HealthCor Management L.P., Capital World Investors, Janus Henderson Group PLC, Frontier Capital Management Co. LLC, BB Biotech AG, Macquarie Group Ltd. and Tekla Capital Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Malcolm Lloyd-Smith, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.
Which major investors are buying Neurocrine Biosciences stock?
NBIX stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Victory Capital Management Inc., Mirae Asset Global Investments Co. Ltd., Standard Life Aberdeen plc, Thrivent Financial for Lutherans, Candriam Luxembourg S.C.A., Rothschild & Co. Asset Management US Inc. and Perceptive Advisors LLC. View Insider Buying and Selling for Neurocrine Biosciences.
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $92.01.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $9.02 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.
What is Neurocrine Biosciences' official website?
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
